Form 4: Adverum Biotechnologies Completes Eli Lilly Merger

Adverum Biotechnologies, Inc. has completed its merger with Eli Lilly and Company, with shareholders receiving cash and contingent value rights.

Summary

• Adverum Biotechnologies, Inc. completed its merger with Eli Lilly and Company, making Adverum a wholly-owned subsidiary of Eli Lilly, effective December 9, 2025.
• The merger followed a tender offer by Eli Lilly's direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation.
• Tendering stockholders received $3.56 per share in cash (the "Cash Consideration") and one non-tradable contingent value right (CVR) per share.
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling up to an aggregate of $8.91 per CVR, upon the achievement of specified milestones.
• Chief Medical Officer Rabia Gurses Ozden's 8,125 Restricted Stock Units (RSUs) and 85,000 Performance Stock Units (PSUs) were cancelled in exchange for cash ($3.56 per unit) and CVRs (one per unit).
• A total of 189,760 out-of-the-money stock options held by the reporting person, with exercise prices ranging from $4.20 to $10.14, were fully vested but cancelled for no consideration at the effective time of the merger.

Sentiment

Score: 7

Explanation: The completion of the merger provides immediate cash value and potential future upside through CVRs for shareholders, which is generally positive. However, the cancellation of out-of-the-money options for no consideration represents a negative for option holders.

Positives

• Shareholders received a cash consideration of $3.56 per share, providing immediate liquidity.
• Shareholders received contingent value rights (CVRs) offering potential additional payments of up to $8.91 per CVR, providing future upside potential.
• The reporting person's Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) were converted into cash and CVRs, providing immediate value and future upside potential.
• Performance Stock Units (PSUs) granted on September 12, 2025, vested 100% upon the change of control event (the merger), ensuring their conversion.

Negatives

• Stock options with exercise prices equal to or greater than the cash consideration ($3.56) were cancelled for no consideration, even if fully vested.
• The reporting person had 189,760 stock options cancelled for no consideration, representing a loss of potential future value if the stock price had risen above the exercise price.

Future Outlook

The future value for former Adverum shareholders includes potential contingent cash payments of up to $8.91 per CVR, dependent on the achievement of specified milestones as outlined in the CVR Agreement.

Industry Context

This acquisition by Eli Lilly and Company of Adverum Biotechnologies, a biotechnology firm, reflects a broader trend of larger pharmaceutical companies acquiring smaller biotech firms to expand their pipelines and intellectual property, particularly in specialized therapeutic areas. The use of Contingent Value Rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future development risks and rewards.

Stakeholder Impact

• Shareholders: Received $3.56 cash per share and one CVR per share, offering immediate value and potential future payments based on milestone achievement.
• Employees (specifically option holders): Those with out-of-the-money options saw them cancelled for no consideration, while RSU/PSU holders received cash and CVRs, converting their equity into merger consideration.
• Adverum Biotechnologies: Now operates as a wholly-owned subsidiary of Eli Lilly, integrating into a larger pharmaceutical structure and potentially benefiting from Eli Lilly's resources and pipeline.

Next Steps

• Achievement of specified milestones for CVR payments, which will trigger contingent cash distributions to CVR holders.

Key Dates

Keywords

Adverum Biotechnologies, Eli Lilly, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, RSU, PSU, Form 4, ADVM, Biotechnology, Pharmaceuticals